Maya, Jessica, Unger, Elizabeth R, Lin, Jin-Mann S et al. · International journal of molecular sciences · 2026 · DOI
This study examined whether genes influence how the immune system's complement proteins work in ME/CFS patients. Researchers found that some ME/CFS patients carry specific genetic variations linked to problems with a particular immune pathway (the alternative complement pathway), creating a subgroup with distinctive immune patterns. This suggests that genetics may explain why ME/CFS affects people differently and could eventually help doctors identify which patients might benefit from specific treatments.
This research provides the first genetic evidence linking specific DNA variations to complement system dysregulation in a subset of ME/CFS patients, suggesting biological heterogeneity in ME/CFS. Identifying disease subgroups through genetic and immunological biomarkers could enable personalized diagnostic and therapeutic approaches, moving beyond one-size-fits-all treatment strategies. This work validates the complement pathway as a therapeutic target worth pursuing in clinical trials.
This study does not prove that these genetic variants cause ME/CFS or that complement dysregulation is the primary driver of illness in all patients. The findings represent association, not causation, and apply only to the identified inflammatory subgroup; most ME/CFS patients may have different underlying mechanisms. External validation in larger, diverse populations is needed before these findings can guide clinical practice.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.